[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100547033":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":56,"collaborators":26,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":26,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":41,"whyStopped":26,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Fudan University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Radiotherapy Arm","ACTIVE_COMPARATOR","Radiotherapy (50Gy\u002F25f), IMRT",[13],"Radiation: Radiotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Chemoradiotherapy Arm","EXPERIMENTAL","2 cycle of chemotherapy, and then radiotherapy of 50Gy\u002F25f，and then another 2 cycle of chemotherapy",[19],"Drug: Chemotherapy",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Chemotherapy","paclitaxel 60mg\u002Fm2, ivgtt; cisplatin 30mg\u002Fm2, ivgtt; 5-FU 500mg\u002Fm2, ivgtt and 500mg\u002Fm2, civ 24h; calcium folinate 200mg; q3w.",[15],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"RADIATION","Radiotherapy","IMRT, 50Gy\u002F25f",[9],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Xingwen Fa, Doctor","CONTACT","+8613651669687","wenxingfan@126.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Fudan University Shanghai Cancer Center","RECRUITING","Shanghai","Shanghai Municipality","212013","China","CN",{"type":48,"coordinates":49},"Point",[50,51],121.45806,31.22222,{"lat":51,"lon":50},[54],{"name":55,"role":35,"phone":36,"phoneExt":26,"email":37},"Xingwen Fan, Doctor",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Kailiang Wu","professor","100547033","phase-3-postoperative-adjuvant-chemotherapy-for-thymic-cancer-fuscc-thymic-3-100547033",false,"NCT06402708","Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)","Postoperative Adjuvant Treatment for Thymic Cancer With Completed Resection (Radiotherapy vs Chemoradiotherapy): A Prospective, Multicenter, Open-label, Phase III, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Voluntarily participate and sign an informed consent form in writing;\n2. Age range from 18 to 75 years old, regardless of gender;\n3. Within 3 months after the surgery is completed;\n4. Histologically diagnosed with thymic cancer;\n5. Complete resection based on surgical records, pathological reports, and postoperative imaging;\n6. Masaoka stage: I-III\n7. No severe hematopoietic function, heart, lung, liver, kidney dysfunction, or immune deficiency;\n8. White blood cells ≥ 3 × 109\u002FL; Neutrophils ≥ 1.5 × 109\u002FL; Hemoglobin ≥ 10 g\u002FdL; Platelets ≥ 100 × 109\u002FL; Total bilirubin ≤ 1.5 times the upper limit of normal value; AST (SGOT)\u002FALT (SGPT) ≤ 2.5 times the upper limit of normal value; Creatinine ≤ 1.5 times the upper limit of normal value;\n\nExclusion Criteria:\n\n1. Having a second primary tumor (excluding cured non malignant melanoma of the skin, papillary thyroid carcinoma, stage I seminomatoma, cervical carcinoma in situ, or other curable tumors that have been tumor free for more than 3 years after treatment);\n2. Symptomatic coronary heart disease, left heart failure, uncontrollable seizures, or loss of self-awareness due to mental illness;\n3. Pregnancy and lactation period;\n4. Patients with drug addiction, chronic alcoholism and AIDS;\n5. Researchers believe that participants are not suitable for this experiment.","ALL","18 Years","75 Years",{"count":71,"type":72},172,"ESTIMATED","INTERVENTIONAL",[75],"PHASE3","The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are:\n\n1. Does adjuvant chemotherapy decrease disease progression?\n2. Does medium dose of three drugs (paclitaxel, cisplatin, 5-FU) well tolerance?\n\nResearchers will compare chemoradiotherapy to radiotherapy to see whether chemoradiotherapy could decrease disease progression or not.\n\nParticipants will:\n\n1. Take radiotherapy (50Gy\u002F25f) with or without 4 cycles of chemotherapy (TPF).\n2. Follow up every 3 months in the first two year, and then every 6 months.",[78],"Thymic Carcinoma",[80,81,82,83],"thymic carcinoma","adjuvant treatment","radiotherapy","chemotherapy","2026-04-22",{"date":86,"type":87},"2026-04-27","ACTUAL",{"date":89,"type":87},"2024-04-09",{"date":91,"type":72},"2030-05-01",{"name":5,"class":6},1]